NCT01520116View on ClinicalTrials.gov

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Stage 1 - ATS907 - Dose 1

QD and/or BID dosing for 28 days

DRUG

Stage 1 - ATS907 - Dose 2

QD and/or BID dosing for 28 days

DRUG

Stage 1 - ATS907 - Dose 3

QD and/or BID dosing for 28 days

DRUG

Stage 1 - ATS907 - Dose 4

QD and/or BID dosing for 28 days

DRUG

Stage 1 - Vehicle

QD and/or BID dosing for 28 days

DRUG

Stage 2 - ATS907 - Dose A - to be selected based on Stage 1

QD and/or BID dosing for 4 days

DRUG

Stage 2 - ATS907 - Dose B - to be selected based on Stage 1

QD and/or BID dosing for 4 days

DRUG

Timoptic

0.5%

Trial Locations (5)

Unknown

Artesia

Glendale

Saint Joseph

Cleveland

San Antonio

Sponsors

Lead Sponsor

Altheos, Inc.
All Listed Sponsors
lead

Altheos, Inc.

INDUSTRY

NCT01520116 - Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension | Biotech Hunter | Biotech Hunter